Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomma Lab InternacionalB de CVMEX:LABB +1.17%66 Price-to-Tangible-Book is 2.31 as of Aug. 02, 2026, which is 49% below its 10-year median of 4.51. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.26 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 836 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks worse than 53.47% on this metric.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Price-to-Tangible-Book or its related term are showing as below:
MEX:LABB'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.28 Med: 4.51 Max: 23.11
Current: 2.31
During the past 13 years, Genomma Lab InternacionalB de CV's highest Price to Tangible Book Ratio was 23.11. The lowest was 2.28. And the median was 4.51.
MEX:LABB's Price-to-Tangible-Book is ranked worse than 53.47% of 836
companies
in the Drug Manufacturers industry
Industry Median: 2.16
vs MEX:LABB: 2.31
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Genomma Lab InternacionalB de CV Price-to-Tangible-Book Related Terms
Genomma Lab InternacionalB de CV Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Price-to-Tangible-Book Chart
MEX:LABB vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Genomma Lab InternacionalB de CV (MEX:LABB) has a Price-to-Tangible-Book of 2.31 as of Aug. 02, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 49% below median its historical median of 4.51. Over the past decade, Genomma Lab InternacionalB de CV's Price-to-Tangible-Book has ranged from 2.28 to 23.11. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #447 out of 836 companies in the Drug Manufacturers industry, placing it in the top 53.5%.
Is Genomma Lab InternacionalB de CV's Price-to-Tangible-Book too high?
Genomma Lab InternacionalB de CV's current Price-to-Tangible-Book of 2.31 is 49% below median its 10-year median of 4.51. Over the past 10 years, this metric has ranged from a low of 2.28 to a high of 23.11. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.16. Genomma Lab InternacionalB de CV's value of 2.31 is 6.9% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #447 out of 836 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Price-to-Tangible-Book compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #447 out of 836 companies for Price-to-Tangible-Book. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.16. Genomma Lab InternacionalB de CV's value of 2.31 is 6.9% above this benchmark. Historically, Genomma Lab InternacionalB de CV's own Price-to-Tangible-Book has ranged from 2.28 to 23.11 over the past decade. While the company's 10-year median is 4.51 vs. the industry median of 2.16, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.16, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Price-to-Tangible-Book of 2.31 is 6.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Price-to-Tangible-Book is 2.31, which is 49% below median its own 10-year median of 4.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.26, compared to a current price of MXN14.67 — trading 15% below its estimated fair value. The current Price-to-Tangible-Book is 2.31, which is 49% below median its 10-year median of 4.51 and 6.9% above the Drug Manufacturers industry median of 2.16. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Price-to-Tangible-Book is 2.31 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.67 is trading 15% below its estimated GF Value™ of MXN17.26.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Price-to-Tangible-Book: 2.31 (49% below median its 10-year median of 4.51)
GF Value™: MXN17.26 vs. price of MXN14.67 (15% below fair value)
Industry Position: 6.9% above the Drug Manufacturers median (#447 of 836)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
